ab108633 Cancer Antigen CA15-3 Human ELISA Kit is intended for the quantitative determination of the Cancer Antigen CA15-3 concentration in human serum.
Breast cancer is the most common life-threatening malignant lesion in women of many developed countries today, with approximately 180,000 new cases diagnosed every year.
There are a number of tumor markers that can help clinicians to identify and diagnose which breast cancer patients will have aggressive disease and which will have an indolent course. These markers include estrogen and progesterone receptors, DNA ploidy and percent-S phase profile, epidermal growth factor receptor, HER-2/neu oncogene, p53 tumor suppressor gene, cathepsin D, proliferation markers and CA15-3. CA15-3 is most useful for monitoring patients post-operatively for recurrence, particularly metastatic diseases. 96% of patients with local and systemic recurrence have elevated CA15-3, which can be used to predict recurrence earlier than radiological and clinical criteria. A 25% increase in the serum CA15-3 is associated with progression of carcinoma. A 50% decrease in serum CA15-3 is associated with response to treatment. CA15-3 is more sensitive than CEA in early detection of breast cancer recurrence.
|Components||1 x 96 tests|
|20X Washing Solution||1 x 50ml|
|CA15-3 Standard set x6||1 unit|
|Enzyme Conjugate Concentrate||1 x 1ml|
|Enzyme Conjugate Diluent||1 x 21ml|
|IgG Sample Diluent||1 x 100ml|
|Mouse Monoclonal anti-CA15-3 coated microtiter plate||1 unit|
|Stop Solution||1 x 11ml|
|TMB Substrate Solution||1 x 11ml|
Our Abpromise guarantee covers the use of ab108633 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Sandwich ELISA||Use at an assay dependent dilution.|
ab108633 has not yet been referenced specifically in any publications.